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Purpose. Abnormal protein deposits including 𝛽-amyloid, found in ageing Bruch’s membrane and brain, are susceptible to
degradation by matrix metalloproteinases (MMPs). In ageing Bruch’s membrane, these MMPs become less effective due to
polymerisation and aggregation reactions (constituting the MMP Pathway), a situation much advanced in age-related macular
degeneration (AMD). The likely presence of this MMP Pathway in brain with the potential to compromise the degradation of
𝛽-amyloid associated with Alzheimer’s disease (AD) has been investigated. Methods. Presence of high molecular weight MMP
species (HMW1 and HMW2) together with the much larger aggregate termed LMMC was determined by standard zymographic
techniques. Centrigugation and gel filtration techniques were used to separate and quantify the distribution between bound and free
MMP species. Results. The MMP Pathway, initially identified in Bruch’s membrane, was also present in brain tissue. The various
MMP species displayed bound-free equilibrium and in AD samples, the amount of bound HMW1 and pro-MMP9 species was
significantly reduced (𝑝 < 0.05).The abnormal operation of theMMP Pathway in AD served to reduce the degradation potential of
the MMP system. Conclusion.The presence and abnormalities of the MMP Pathway in both brain and ocular tissues may therefore
contribute to the anomalous deposits associated with AD and AMD.
1. Introduction
Alzheimer’s disease (AD) and age-related macular degener-
ation (AMD) are neurodegenerative disorders that share a
strong correlationwith advancing age and are both character-
ized by similar extracellular deposits. Common constituents
within the deposits include vitronectin, apolipoprotein E,
amyloid P, amyloid 𝛽 (A𝛽), lipids, inflammatory mediators,
and complement components [1–4]. Whereas AD shows the
abundant presence of aggregated A𝛽 peptides and hyper-
phosphorylated tau protein in brain, AMD is characterized by
deposition of lipids, lipoproteinaceous debris, and oxidized
and damaged extracellularmatrix (ECM) components within
Bruch’s membrane of the eye [5–7].
Deposits accumulate when there is an imbalance between
production and clearance. In Bruch’s membrane, tightly
coupled processes of synthesis and degradation serve to
continuously turn over the ECM of the membrane, thereby
maintaining its structural and functional characteristics. The
degradation pathway is mediated by matrix metallopro-
teinases (MMPs) and primary gelatinase components are
MMP2 andMMP9, the former being the constitutive enzyme
and the latter the inducible form.TheseMMPs are released as
inactive proenzymes (pro-MMPs) and on activation (by pro-
teolytic cleavage of a small peptide) are capable of digesting all
components of an ECM [8–11]. MMPs are involved in many
diverse tissue remodelling activities including wound healing
and embryonic development, and increased activities are
associated with pathological conditions as varied as cancer,
rheumatoid arthritis, and cardiovascular diseases [12–16].
In normal ageing, the increased thickness of Bruch’s
membrane [17, 18], the deposition of normal and abnormal
ECM material [6], increased cross-link formation (oxidative
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and nonenzymatic glycosylation leading to advanced glyca-
tion end-products, AGEs, and ALEs) [19], and the accumu-
lation of lipid-rich debris [20, 21] are changes that implicate
a disturbance in the ECM turnover of the membrane. Irre-
spective of an age-related increase in levels of pro-MMP2 and
pro-MMP9 in Bruch’s membrane, the amount of oxidized,
denatured, and damaged collagenous substrate was observed
to increase, accounting for nearly 50% of total collagen in
elderly membranes [6, 22]. In advanced ageing associated
with AMD, despite a 2-fold increase in the total level of
pro-MMP9, levels of active-MMP2 and active-MMP9 were
reduced by 50% compared to age-matched controls [23].Thus
diminished degradative capacity appears to shift the balance
towards accumulation of normal and abnormal constituents.
Age-related mechanisms in Bruch’s membrane that result
in increased levels of pro-MMPs but decreased levels of
activated enzymes are poorly understood.TheMMPPathway
(Figure 1(a)) shows the myriad of reactions undergone by
free pro-MMPs to produce the highmolecular weight species
designated HMW1, HMW2, and the large macromolecular
weight MMP complex (LMMC). A further complication is
that all these species exist in a free and bound equilibrium
and therefore the operation of the MMP Pathway effectively
sequesters-free pro-MMPs. The likely impact of these com-
petitive reactions on the activation of the constitutive MMP2
enzyme is illustrated in Figures 1(b) and 1(c).
Pro-MMP2 activation ismediated by anothermetallopro-
teinase, a transmembrane enzyme MMP14, in combination
with a tissue inhibitor of MMPs and TIMP2 [24–26]. The
activation requires twomolecules ofMMP14; the firstMMP14
molecule binds TIMP2 and this enables the formation of
the ternary complex with pro-MMP2. A second MMP14
molecule then cleaves the proform to release active-MMP2
[27].Thus, efficient activation requires the presence ofMMPs
andTIMPs in optimumconcentrations. Competing reactions
that reduce the level of free pro-MMP2 are the covalent
interaction with pro-MMP9 to form HMW2, binding within
the extracellular matrix, and incorporation of pro-MMP2
into the LMMC complex. In AMD, the formation of HMW2
is enhanced by the >3-fold increase in the free level of pro-
MMP9 resulting in decreased levels of the active-MMP2
enzyme [23].
In brain, A𝛽 is formed by the sequential cleavage of the
membrane-bound amyloid beta precursor protein (A𝛽PP)
by 𝛽-secretase (BACE1) and the presenilin-dependent 𝛾-
secretase. Proteolysis by 𝛾-secretase leads to a variety of A𝛽
species, themajor portion (∼80–90%) being of 40 amino acid
residues (A𝛽40) followed by a 42-amino acid peptide (5–10%,
A𝛽42), the latter being more hydrophobic and constituting
the main deposit in the brain [28]. Similar pathways are also
known to be present in the retinal pigment epithelium (RPE)
accounting for the presence of A𝛽 in Bruch’s membrane
[29, 30].
Removal of A𝛽 occurs via transport mechanisms and
enzymatic hydrolysis. Transport is by drainage along perivas-
cular basement membranes and receptor mediated translo-
cation across the blood-brain barrier (BBB) [31, 32]. The
A𝛽 degrading enzymes (ADEs) comprise over 20 multifunc-
tional metalloendopeptidases and include neprilysin (NEP),
insulin-degrading enzyme (IDE), angiotensin-converting
enzyme (ACE), endothelin-converting enzyme (ECE), and
MMPs [33–36]. Of these various enzyme systems, only
MMP9 was able to degrade fibrillar A𝛽 (fA𝛽) in vitro and
compact plaques in situ [37].
Measurement of enzymatic activities in postmortem
brains showed that NEP, IDE, ACE, ECE-1, ECE-2, and
MMPs were all higher in AD [37, 40–44]. These studies are
perhaps verified by cell culture analyses that have shown
upregulation of ADEs such as NEP, ECE, ACE, ECE-2, IDE,
and MMP2, MMP3, and MMP9 on exposure to A𝛽 [42, 43,
45–47].
Thus in AD, despite the elevated presence of ADEs,
the abnormal A𝛽 product continues to accumulate. This
anomalous situation (of high levels of latent enzymes and
reduced substrate degradation) is similar to that observed
in normal and abnormal ageing of Bruch’s membrane. It is
therefore highly likely that MMP transformations akin to the
MMP Pathway in Bruch’s membrane (Figure 1(a)) may also
operate in brain tissue leading to sequestration of free MMP
species, curtailing their activation potential. There is some
evidence for the presence of high molecular weight MMP
species (HMW1 and HMW2) in both human AD brain and
in animal models of the disease [48, 49].
In this preliminary investigation, we have demonstrated
the presence of theMMPPathway in brain tissue and assessed
its operation in donors with AD.
2. Materials and Methods
2.1. Tissue Preparation. After securing Research Ethics Ap-
proval, brain donor samples from the parietal cortex (∼0.5–
1 g/donor) were obtained from Brains for Dementia Research
Unit/Bristol Brain Bank of Bristol University, UK. Parietal
cortex tissue was chosen because it was readily available
in sufficient quantity to optimise the analytical procedures
described in this study. Tissue samples were transported
to the laboratory on dry ice and stored at −70∘C until
experimentation. Altogether, 4 control samples (age 81 ± 5
years; postmortem delay 37.5±7 hours; Braak stage 1.8±0.4)
and 5 AD affected samples (age 79 ± 4; postmortem delay
37 ± 21 hours; Braak stage 5.4 ± 0.5) were made available for
these studies (mean ± SD, Table 1).
Brain samples were processed to obtain three tissue
fractions: homogenates, supernatants, and insoluble tissue
pellets. About 50–100mg wet weight of sample was homoge-
nized in 1.0mL Tris-buffered saline (TBS, 50mMTris, 0.15M
NaCl, 10mM CaCl2, and 0.02% sodium azide, pH 7.4) using
20 strokes of a hand held 3.0mL Potter-Elvehjem homoge-
nizer (clearance 0.004–0.006 in, Sigma-Aldrich, UK). After
withdrawal of a 50𝜇L aliquot for protein estimation by the
Folin-Ciocalteu method [50], some of the homogenates were
spun at 10,000𝑔 for 5 minutes to obtain the supernatant and
pellet fractions. Supernatant and pellet proteins were also
measured.
Bruch’s membrane was prepared from the eye of a donor
aged 76 years, obtained from the Bristol Eye Bank, UK, as
previously described [23]. Briefly, a circumferential incision
wasmade 5mmposterior to the sclera sulcus and the anterior
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Table 1: Details of control and AD donors utilized in the study.
Donor
number Status
Age
(years) Sex Histological diagnosis
Postmortemdelay
(hours) Braak stage
1 Control 74 F No significant abnormalities 39.5 1
2 Control 86 F No AD, moderate CAA 32 2
3 Control 85 M No significant abnormalities 30.5 2
4 Control 79 F No significant neuropathologicalabnormality 48 2
5 AD 78 M ADmoderate to severe 49.5 6
6 AD 81 M AD probable 11 5
7 AD 85 F
AD definite, moderate
atherosclerotic small vessel
disease, moderate to marked
CAA
14 5
8 AD 73 F AD definite, moderate CAA 50.5 5
9 AD 78 F AD definite 61 6
AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy.
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Figure 1: (a)TheMatrixMetalloproteinase (MMP) Pathway.The gelatinase components comprise the pro- and active forms of themonomeric
MMP2 and MMP9, the high molecular weight forms denoted by HMW1 and HMW2, and the large macromolecular weight MMP complex
termed LMMC consisting of HMW1 andHMW2, pro-MMP9, and a trace of pro-MMP2. Apart from LMMC, all other gelatinase components
have been shown to exist in a free/bound equilibrium (pathway constructed from reference [38].) (b) Activation scheme for pro-MMP2. (c)
Competing reactions for free pro-MMP2. These are primarily binding, activation, covalent interaction with pro-MMP9 to form the HMW2
species, and incorporation into the LMMC complex (constructed from [24–27, 38, 39]).
segment discarded. The remaining globe was opened in the
shape of a Maltese cross and the four segments separated and
transferred to a Petri dish containing TBS. Using a pair of fine
forceps, the retina and vitreous were carefully removed. The
exposed monolayer of retinal pigment epithelial (RPE) cells
was brushed away with a camel’s hair brush exposing Bruch’s
membrane. After transferring the preparation to fresh TBS,
an 8mm trephine was used to remove a full thickness button
of Bruch’s membrane to sclera. Finally, the Bruch’s-choroid
sample was removed by blunt dissection from the underlying
sclera.
2.2. Identification of MMP Species Except LMMC. Homoge-
nates were screened for the presence of MMP species by
substrate gelatin zymography [22, 23, 38, 39]. Zymography
involves the electrophoretic separation of MMPs according
tomolecular weight, and their identification following degra-
dation of the substrate incorporated into the gel. It is a
relatively simple, quantifiable, and functional assay forMMPs
[51–53]. Briefly, proteins are separated in a polyacrylamide
gel containing a MMP substrate (such as gelatin) and the
presence of sodium dodecyl sulfate (SDS) in the gel leads
to denaturation of MMPs [54]. After electrophoresis, the
4 Journal of Neurodegenerative Diseases
gel is incubated in Triton X-100 which exchanges for SDS
leading to partial activation of the MMPs [55–57]. Gels are
then incubated in activation buffer allowing the MMPs to
digest the substrate [52, 58]. Following staining of the gel with
Coomassie blue, theMMP containing regions are observed as
transparent (or clear) bands against a blue background.These
bands are then quantified by densitometry [56, 59].
The level of individualMMP species in both homogenates
and supernatants was quantified to obtain the amount of a
given species in the bound state.
Because MMPs exist in an equilibrium between bound
and free species, tissue homogenizationwill inevitably lead to
dilution and this may alter the amount bound and the extent
of this redistribution will be dependent on the magnitude
of the dissociation constants. To assess this phenomenon,
homogenates were diluted and after a 6 hour incubation, the
amount of free MMPs in the supernatants was determined.
Brain tissue (346mg) from control donor number 2 was
homogenized in 4.0mls Tris buffer and six 0.5mls aliquots
prepared. Three of these were diluted 1/10 by addition of
4.5mls TBS (termed preparation A) and all tubes incubated
at 37∘C for 6 hours. After incubation, the samples were
centrifuged at 3000×g for 20mins to obtain pellet and
supernatant fractions. Supernatants from the 0.5mls samples
were then diluted 1/10 with TBS (termed preparation B). Both
preparations were then subjected to zymographic analysis.
Homogenization of the tissue sample results in the release
of the LMMC complex into the supernatant. Use of sodium
dodecyl sulfate (SDS) for preparing samples for zymogra-
phy results in dissolution of the LMMC particle into its
constituents. Therefore the measured MMP content in the
supernatant will include both free MMP species and those
released from the LMMC.
2.3. Isolation of the LMMCComplex andDetermination of Free
Levels of MMP Species. LMMC is a large macromolecular
weight complex found in the extracellular compartment with
its constituents HMW1, HMW2, pro-MMP9, and some pro-
MMP2, all held together by noncovalent attachment. It is
therefore easily dispersed in SDS containing buffers and thus
cannot be examined directly in supernatants by zymographic
techniques. Because of its large size, it is excluded from
Sepharose CL-6B gel filtration media and exits the column
in the void volume with a V𝑒/V𝑜 ratio of about 1.0. Subsequent
zymographic identification of its constituents at the forefront
of the elution profile is indicative of the presence of the
LMMC complex.
The protein content of the supernatant fraction was
adjusted to 3.57mg/0.8mls and applied to a Sepharose CL-
6B filtration column (30 cm × 1.5 cm i.d.) preequilibrated
with TBS. Flow rate was adjusted to 0.6mls per minute
and 1.2mls fractions collected for a period of 1.5 to 2
hours. The protein profile of the chromatography run was
obtained by measuring the absorbance of the fractions at a
wavelength of 280 nm. Fraction aliquots were then processed
for zymographic analysis as described below.The intensity of
the bands of individual gelatinaseswas plotted as a function of
eluted volume (V𝑒/V𝑜) to determine their relative distribution
between the LMMC species and the free state.
2.4. Gelatin Zymography. Samples for zymography were
mixed 1 : 1 (v/v) in SDS sample buffer (62.5mM Tris, 10%
glycerol, 4% SDS, and 0.05% bromophenol blue), vortexed,
and spun (10,000𝑔/5mins) and 30 uL aliquots applied to gel
lanes.
For zymography, 10%SDS-PAGEgels (1.0mm thick)were
prepared containing a 4% stacking layer and 0.1% gelatin
in the separating layer. Samples for analysis were loaded
into lanes together with prestained protein molecular weight
markers (Invitrogen, UK) and 10% foetal calf serum (FCS,
Sigma-Aldrich, UK) as an internal standard to correct for
gel-to-gel variation in background staining. Electrophoresis
was performed using the X Cell SureLock Mini-Cell system
(Invitrogen, UK).
After electrophoresis (180V, 1 hour), the gels were
removed from their cassettes, rinsed in distilled water, and
incubated for two half-hour periods in 2.5% Triton X-100 to
remove SDS and renature the proteins (as described earlier).
They were then transferred to reaction buffer (50mM Tris-
HCI, 10mM CaCl2, 75mM NaCl, and 0.02% NaN3, pH 7.4)
and incubated at 37∘C for 20 hours to allow proteolytic
digestion of the gelatin substrate. Gels were rinsed again
in distilled water and stained with Coomassie blue (0.1%
Coomassie blue R-250, 40% methanol, 10% acetic acid) for
30 minutes. Destaining was carried out for 30 minutes with
40% methanol and 10% acetic acid solution.
MMP activity was observed as transparent bands on a
blue background. These gels were scanned at a resolution
of 2400 dpi (Epsom 3490 scanner) and stored in JPEG
format.The colour imageswere uploaded into theQuantiscan
software package (Quantiscan Version 3.0, Biosoft, Cam-
bridge, UK) in grey-scale format, colours inverted so that
MMPs were now visualised as dark bands against a whitish
background, and after background correction, the area under
the densitometric scan for an individual gelatinase band was
quantified.
2.5. Statistical Analysis. All data are presented as mean ± SD
(𝑛) with n being the number of donors. Student’s 𝑡-test was
used to assess significance between the amount of free pro-
MMP9 in the elution profiles between the control and AD
samples.
3. Results
3.1. Components of the MMP Pathway and Free/Bound
Levels. A zymographic analysis of MMP species present
in homogenates and their respective supernatants obtained
from four control and four AD donor brains is shown in
Figure 2. Sample from AD donor 8 was lost due to accidental
shattering of the homogenizer tube. The amount of protein
applied per lane for homogenate and supernatant fractions
was 67 ± 1 𝜇g and 44 ± 4 𝜇g, respectively. For comparative
purposes, the MMPs normally present in extracts of Bruch’s
membrane and in foetal calf serum (FCS) are also shown.
The highmolecular weight components of theMMPPathway
(HMW1 and HMW2) together with pro-MMP9 were clearly
identifiable in the homogenates (Figure 2(a)). Removal of
the insoluble (i.e., the pellet) fraction from the homogenate
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Figure 2: Components of the MMP Pathway in brain tissue. The MMP content of brain homogenates is shown in Gel A and the resulting
profiles following centrifugation to obtain the supernatant fraction in Gel B. Altogether, 4 control and 4 AD brain samples were examined.
HMW2 and pro-MMP9 were the predominant MMP species present in the homogenates with lower levels of HMW1. Pro-MMP2 was below
the detection limit. Centrifugation to remove insoluble and membranous material resulting in the supernatant fraction showed a marked
reduction in the level of HMW2 signifying that this species exists largely in the bound fraction. Supernatant fractions also demonstrated the
presence of pro-MMP2. The molecular weights of MMP species present in brain were similar to those encountered in Bruch’s membrane of
the eye. Densitometry was undertaken to calculate the percentage of bound MMP species using (1) in the manuscript. The gels demonstrate
the presence of the MMP Pathway in brain tissue.
to obtain the supernatant fraction showed considerable loss
of the HMW2 signal indicative of this component being
largely in the bound form (Figure 2(b)). Levels of pro-MMP2
were too low to be detected in the homogenate fractions but
just discernible in the supernatant fractions. The molecular
weights of the MMP species present in brain samples were
similar to those determined in Bruch’s membrane.
Zymographic gels of Figure 2 showed considerable vari-
ation in the levels of individual MMP species between the
various donors examined. This variation was quantified by
undertaking a densitometric analysis, with activity being
expressed as densitometric gel band area per 𝜇g protein
(Table 2(a)). The only significant difference was the lowered
activity of HMW1 in the homogenate fractions of AD donors
suggestive of lowered binding (𝑝 < 0.05).
MMPs present in the supernatant fraction are generally
considered to be “free” whereas those in the pellet fraction
are considered to be bound. However, MMPs bound within
the LMMC complex also exist in the supernatant fraction
and these are released on sample preparation for zymography.
Thus the MMP species present in the supernatant fraction
(Figure 2(b)) represents both free and those normally bound
within the LMMC species. For this reason, it is best to
consider MMPs in the supernatant fraction as being in the
mobile phase. A procedure to separate LMMC from free
MMPs by gel exclusion chromatography is described later.
In order to obtain the amount of MMP species present
in the bound and mobile compartments, it would have
been ideal to quantify levels in the supernatant and pellet.
However, attempts at solubilisation of pellet proteins resulted
in protein precipitation in the gel wells together with poor
resolution and distortion of the MMP bands (results not
shown). An alternative strategy was adopted, utilizing MMP
quantification in the homogenate and supernatant fractions,
to calculate the percentage in the bound/mobile compart-
ments.
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Table 2: Brain MMP levels and their relative distribution between bound and mobile compartments.
(a) Gelatinase bands in the zymograms of Figure 2 were quantified by densitometry and activity expressed as gel band area per 𝜇g protein (4 controls and
4 AD donors). Level of HMW1 in the homogenate of AD samples showed a significant reduction compared to controls. AD, Alzheimer’s disease; NDet, not
detected; ∗𝑝 < 0.05.
MMP species
MMP activity (gel band area/𝜇g protein) mean ± SD
Homogenate Supernatant
Control AD Control AD
HMW2 35.9 ± 24.2 35.5 ± 7.7 14.7 ± 13.2 10.4 ± 1.8
HMW1 6.4 ± 3.8 1.8 ± 2.0∗ 8.3 ± 3.2 6.9 ± 5.0
Pro-MMP9 65.7 ± 48.6 51.8 ± 20 108 ± 75 111 ± 37
Pro-MMP2 NDet NDet 2.33 ± 1.2 2.7 ± 0.4
(b) For each MMP species in Figure 2, the gel band area per 𝜇g of protein was determined for both homogenates and supernatants and the percentage of
species bound was calculated using (1). HMW2 was observed to be tightly bound to the membranous or insoluble extracellular component in brain tissue.The
amount of HMW1 and pro-MMP9 bound was significantly reduced in AD. Control donors: numbers 1–4; AD donors: numbers 5–7, 9. ∗𝑝 < 0.05.
MMP species Percentage of bound MMP species (mean ± SD)
Control AD
HMW2 93.8 ± 5.0 90.3 ± 1.3
HMW1 47.3 ± 24 13.3±14.3∗
Pro-MMP9 55.5 ± 11.8 28.5±15.4∗
Pro-MMP2 0 0
In the eight brain samples used to obtain Figure 2, the
percentage of total protein in the tissue sample that was
present (after homogenization and centrifugation) in the
supernatant fraction was calculated as 32 ± 3% (Mean ± SD).
Therefore, for a given MMP species, if 𝑥 is the gel band area
per microgram protein in the supernatant and 𝑦 is the gel
band area per microgram protein in the homogenate, the
percentage of the species bound in the pellet (i.e., excluding
that in the LMMC) is given by
% bound =
(𝑦 − 0.32𝑥)
𝑦
× 100. (1)
Since the protein levels in the homogenate and supernatant
samples applied to the gels were known and the values of
𝑥 and 𝑦 for a given MMP species could be calculated from
a densitometric scan of the gels, it was possible to calculate
the percentage bound (Table 2(b)). In all donor samples, the
HMW2 species existed in predominantly the bound state.
In control tissue, about half of the HMW1 and pro-MMP9
content was found in the bound fraction whereas in AD
donors, this binding was significantly reduced (𝑝 < 0.05).
Bound pro-MMP2 species was not observed in any of the
samples.
In the above study, 50–100mg of tissue was homogenized
in 1.0mL TBS and this variation in the amount of tissue
used between donors may have altered the distribution of
bound and free species, the degree being dependent on the
magnitude of the dissociation constants. To assess the extent
to which this may have influenced the binding data, tissue
homogenate from donor number 2 was diluted tenfold and
effects on the bound versus free level determined. To facilitate
the comparison on the gels, supernatant from the concen-
trated homogenate was also diluted prior to zymography. If
greater amounts of the bound formwere released on dilution,
then band intensities in the diluted samples should be higher.
After a tenfold dilution of the homogenate, the levels of
HMW2, HMW1, and pro-MMP2 were too low to be detected
on the zymograms (Figure 3). Pro-MMP9, being present
at much higher levels in tissues, was however detectable.
There was no statistical difference in the level of pro-MMP9
present in the supernatants of undiluted and diluted samples
(densitometric analysis of levels present in preparations A
and B (see Materials and Methods) were 526 ± 39(3) and
497±125(3) arbitrary units (mean ± SD(𝑛)), respectively.The
lack of increase in the level of pro-MMP9 in the supernatant
of the diluted homogenate suggests that this MMP species
remains tightly bound.
3.2. LMMC and Free MMPs in Brain Tissue. Supernatant
extracts were obtained from four control and five AD donor
samples and the protein content of each preparation was
adjusted to 3.57mg/0.8mls. A 50𝜇L aliquot was removed for
zymography and the remainder fractionated by gel filtration
chromatography on a Sepharose CL-6B column preequili-
brated with TBS. The resulting fractions were then subjected
to zymography.
A representative zymographic analysis of the fractions
following elution is shown for two control and twoADdonors
in Figure 4. The gel lanes labelled “Ext” show the content of
MMP species present in the original extract applied to the
fractionation column. All these extracts were dominated by
the presence of pro-MMP9 but pro-MMP2 levels were only
discernible in donors 1 and 9. Elution of these extracts was
associated with dilution of the MMP species such that band
intensity in the corresponding fractions was considerably
reduced.
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Figure 3: Effect of sample dilution on the release of bound MMPs. Supernatants from the undiluted and diluted brain homogenate
(preparations A and B adjusted for dilution as described in the text) were subjected to zymographic analysis. Only the predominant pro-
MMP9 species was detected but there was no significant difference in levels between preparations A and B. Lanes 1–3, preparation A. Lanes
4–6, preparation B.
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Figure 4: Presence of LMMC in brain tissue. Brain supernatant preparations (3.35mg protein/0.75mls) were fractionated on a gel filtration
column (SepharoseCL-6B) and the resultant fractionswere examined by zymography. Representative sampleswere obtained from two control
(Gels 1 and 2) and two AD (Gels 7 and 9) donors. Gel lanes labelled Ext represent the content of MMP species present in the original
supernatant extract applied to the column. The fractionation procedure resulted in considerable dilution of the MMP species. Due to its
large size, the LMMC complex is expected to be appear at the elution forefront (fractions 11–13) followed by elution of the free MMP species
(fractions 24 onwards). In control samples, LMMC constituents (HMW2 and pro-MMP9) are observed at the elution forefront but the gels
show absence of free MMP species. In AD samples, MMPs associated with the LMMC complex are just discernible at the elution forefront
but the gels are dominated by the presence of free MMP species.
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Figure 5: Densitometric quantification of MMP species following gel filtration and zymography. Scans were obtained from the zymograms
in Figure 4 and are plotted as level of MMP species versus normalised elution volume (V𝑒/V𝑜). In the control plots, MMP species present were
associated with the LMMC complex without any detectable amounts of free species. The AD plots were dominated by the copious presence
of free HMW1 and pro-MMP9 species. Free HMW2 was not detected in any of the samples examined. Note the nearly 6-fold higher vertical
scale in the pro-MMP9 plot compared to the HMW1 plot.
The LMMC complex, due to its large size and exclusion
from the column, is expected to be eluted at the forefront
of the elution profile (fractions 11–13). Subsequent disintegra-
tion of the complex into its constituent MMP species during
preparation for zymography results in the appearance of char-
acteristic MMP species in the fractions at the elution front.
Free MMP species, due to their low molecular weight, are
expected to be eluted much later (fractions 24 onwards). In
control samples (donors 1 and 2), HMW1, HMW2, and pro-
MMP9 species were present at the elution front (signifying
the presence of the LMMC complex) but free MMPs were
not detected in the later fractions implying that most of the
MMP species present in the supernatant was bound within
the LMMC complex. In AD donor number 7, pro-MMP9
was discernible at the elution forefront showing the presence
of LMMC but the vast majority of the species was present
in the free form (eluting later in the fractionation profile).
In AD donor 9 also, a trace of pro-MMP9 was present in
the region associated with the LMMC complex (fraction 12)
but the major signal was due to free HMW1 and pro-MMP9
eluting much later.
The photographic reproduction of the gels in Figure 4
suffers from lack of clarity and for quantitative purposes, den-
sitometric scans were undertaken (Figure 5). Also included in
Figure 5 are the absorption profiles of the fractions at 280 nm
and these showed a predominant peak at the elution front.
This not only reflects absorption by proteins but is largely
due to light scatter by lipid-rich membranous aggregates
appearing in the void volume which were too small to be
removed by the centrifugation of the tissue extract. Figure 5
confirms the results from the gels in that control samples
(donors 1 and 2) were dominated by the presence of LMMC
with undetectable levels of free species. AD samples (donors
7 and 9) showed little or no HMW1 and HMW2 in the
LMMC region but the presence of considerable free levels of
HMW1 and pro-MMP9. It is unlikely that these differences
between control and AD samples were due to postmortem
instability of the LMMC complex for the following reason.
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Figure 6: The relative distribution of HMW1 and pro-MMP9 in the LMMC complex and the free compartment. Data were obtained from
the elution profiles of four control (numbers 1–4) and five AD (numbers 5–9) donors. In control donors, pro-MMP9 was clearly associated
with the LMMC complex with some free pro-MMP9 in two of the donor samples. However the major portion of pro-MMP9 in AD samples
existed in the free form (𝑝 < 0.05). HMW1 when present in control samples was complexed within the LMMC without any detectable free
levels. In AD samples, the majority of the HMW1 species was present in free solution.
Control donors 1 and 2 did not show detectable levels of free
MMP species despite postmortem times of 39.5 and 32 hours.
However, AD donor 7 with postmortem time of 14 hours
showed the copious presence of both free HMW1 and pro-
MMP9.
The elution profiles corresponding to pro-MMP9 and
HMW1 species for all four control and five AD samples are
depicted in Figure 6. In control samples, pro-MMP9 was
present at the elution front indicative of the LMMC complex
with some of the species present in the free form. AD samples
also showed the presence of pro-MMP9 associated with the
LMMC complex but the majority of the species existed in
the free form. A quantitative assessment of free pro-MMP9
(by measuring the areas under the free MMP traces) showed
significantly elevated levels in AD (control 93 ± 90(4)mm
2,
AD 556 ± 440(5)mm
2, mean ± SD(𝑛), and 𝑝 < 0.05).
In the supernatant, theHMW1 species, when present, was
associated exclusively with the LMMC complex in control
donors. In AD samples however, most of the HMW1 species
was present in the free form.
4. Discussion
Gelatin zymography is an excellent technique for the identifi-
cation of MMP activity associated with monomeric or cova-
lently linked polymeric species but is prone to misinterpreta-
tion regarding physiological activity within the intact tissue.
Pro-MMP2 andpro-MMP9, for example, are released into the
extracellular compartment as inactive enzymes, but exposure
to SDS in the zymographic buffers leads to conformational
changes that expose the catalytic site making the enzyme
partially “active.” Thus proteolytic activity is observed on
the zymogram gels whereas physiologically, the enzymes are
latent. Enzymatic activity on zymographic gels associated
with pro-MMPs therefore only reflects potential substrate
availability for activation. Active-MMPs are identified easily
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on zymographic gels due to their lower molecular weights
(due to removal of the inhibitory peptide), running just below
their parent proforms. However physiologically, these forms
may also be inactive due to noncovalent binding of tissue
inhibitors of MMPs (TIMPs). TIMPs are disassociated in
the presence of SDS in the sample buffers for zymography.
Therefore zymographic data requires cautious interpretation
when extrapolating to the situation in intact tissue.
Analysis of intact brain tissue using techniques of in situ
zymography or immunochemical localization cannot distin-
guish between latent and active forms of MMPs, between
monomeric and polymeric forms, and does not give an indi-
cation of the presence of a bound-free equilibrium for specific
species. Homogenization and subsequent electrophoretic
separation of MMP species according to molecular weight
(as part of the zymographic technique) allow identification
and quantification of latent and active-MMP species and of
high molecular weight complexes that are covalently linked.
In the work of Backstrom et al., 1992 [48], brain hippocampal
samples were disintegrated by vortex-mixing and sonication
in the presence of SDS buffers and subsequent zymography
showed the presence of four MMP species denoted as MP-
70, MP-100, MP-130, and another MW higher than 205 kDa.
These species were equivalent to the current designation from
analysis of Bruch’s membrane and other ocular tissues of pro-
MMP2, pro-MMP9, HMW1, and HMW2, respectively [60].
There are two major drawbacks to tissue disruption in the
presence of SDS buffers. Firstly, noncovalently bonded high
molecular weight aggregates will also be solubilised; that is,
the LMMC complex cannot be identified, and secondly, the
bound/free equilibrium will be disrupted because SDS will
also remove the bound species.
Homogenization in Tris buffers (in the absence of SDS)
and centrifugation is expected to release intact the noncova-
lently bonded MMP complexes into the supernatant fraction
for further analysis. It could be argued that complexes such
as LMMC arise due to aggregation of free entities following
the homogenization procedure. If this was the case, then
higher levels of free MMP species should lead to higher
levels in the LMMC complex. However, as shown in Figure 6,
despite the much higher free level of pro-MMP9 and HMW1
in Alzheimer’s samples compared to control, the amount
present in the LMMC was much less than what would be
expected if spontaneous aggregation was occurring.
Centrifugation of the homogenate to provide particulate
and supernatant fractions allows an analysis of the bound-
free distribution of a given MMP species. But this homog-
enization procedure could interfere with the bound-free
equilibrium in that it may lead to dissociation of the species
on dilution or the homogenization may expose hidden
binding sites leading to greater sequestration. However as
shown in Figure 3, pro-MMP9 was found to be tightly bound
and even a 10-fold dilution did not disturb the bound-free
equilibrium. More work is required to assess the dynamics
of the equilibrium perhaps by determining the dissociation
constants for individual MMP species.
The major gelatinase species associated with A𝛽
metabolism are MMP2 and MMP9 [61]. In most tissues
(including brain), basal pro-MMP9 levels comprise themajor
MMP species and being “inducible,” pathophysiological
signals arising from neovascular, inflammatory, or toxic
metabolites such as A𝛽 result in greater expression of
the latent form [33, 62–64]. Despite greater expression of
pro-MMP9, these reported studies did not show increased
active-MMP9. In the present study also, active-MMP9
was not observed on any of the gels and therefore the
physiological importance for MMP9 involvement in A𝛽
metabolism must remain unresolved.
By contrast, pro-MMP2 is regarded as a constitutive
enzyme with an increase in active levels in cultured neuronal
cells on exposure to A𝛽 [45]. The upregulation of these
MMPs in AD brain and in cell cultures exposed to A𝛽
suggests an important role for these enzymes in the disease
process. The perplexing question remains as to why, despite
the increased expression of these enzymes, levels of A𝛽
continue to accumulate. It is likely that the alternative route
for removal of A𝛽, namely, transport across the BBB,may also
be compromised but the relative contribution of this pathway
to the removal of A𝛽 is not known.
Increased expression does not necessarily translate to
increased enzymatic activity because, as stated earlier, these
pro-MMPs require the catalytic removal of a small inhibitory
peptide for activation. Increased expression of pro-MMPs
simply serves to elevate the amount of proenzyme avail-
able for the activation process. The actual amount available
for activation is dependent on the relative contribution of
secondary processes that can manipulate these levels by
binding, cross-linking/polymerisation, and/or sequestration
into highermolecular weight complexes. As explained earlier,
in AMD, the >3-fold increase in free pro-MMP9 increased
the complexation with pro-MMP2 to form HMW2 (via the
MMP Pathway) resulting in decreased levels of active-MMP2
[23]. The operation of a similar pathway in brain could
be informative regarding the free levels of pro-MMP2 and
pro-MMP9, their potential for activation, and their likely
contribution to degradation of A𝛽.
In agreement with other studies, levels of pro-MMP9 in
brain were always higher than levels of pro-MMP2 [33, 48,
49]. Quantitative estimations showed considerable variation
in the level of MMP species between donors. In the case
of pro-MMP9, for example, the standard deviations were
between 33 and 74% of mean values in the various fractions
analysed. Similar variation (51–91%) was observed in the
analysis by Backstrom et al., 1992 [48] utilizing tissue from
five control and seven AD donors. These authors using
samples from the hippocampus also showed elevated levels of
pro-MMP9 inAD, a finding not apparent in the present study.
The reason for the discrepancy may be the high standard
deviations, low donor numbers, or topographical variations
since we examined parietal regions.
High molecular weight gelatinase species of 130 and
280 kDa (corresponding to the current designation ofHMW1
and HMW2, resp.) had previously been noted in brain tissue
but the relevance of these findings to control of free MMP
levels was not investigated [48, 49, 65]. These studies also
demonstrated elevated level ofHMW1 in humanAD [48] and
elevated level of HMW2 in a canine model of AD [49].
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The HMW2 species was virtually all bound in both
control and AD brain samples. Of the total amount of
HMW1 and pro-MMP9 present, about 50% was bound in
controls but this binding was significantly reduced in AD
(𝑝 < 0.05). Whether the “unbound” fraction (resident in the
supernatant fraction) existed in a truly “free” form or in an
equilibriumwith LMMCwas investigated using gel exclusion
chromatography.
In control brain supernatant samples, the content of
HMW1 and HMW2was associated with the LMMC complex
with the virtual absence of free forms. Pro-MMP9 was also
associatedwith LMMCbut some free pro-MMP9was present
in half of the control donors examined (Figure 6). Thus,
despite the high content of HMW2 and pro-MMP9 in whole
tissue, the free level of these species was very low. In AD brain
samples, the amount of MMPs associated with LMMC was
generally low indicative of lowered levels of this complex.
Correspondingly, free HMW1 and pro-MMP9 species were
present in all AD samples (Figure 6).
We need to consider the possibility that the LMMC
complex may be an artefact arising from aggregation of
MMP species with released cellular components during the
homogenization procedure. In control tissue (Figures 5 and
6) there is very little free HMW1, HMW2, or pro-MMP9 and
it could be argued that these species may be aggregating with
released cellular components to form the LMMC complex.
However this would seem unlikely since in AD samples,
very high levels of free HMW1 and pro-MMP9 were present
without a corresponding increase in the level of LMMC.
LMMC is also present in Bruch’s membrane that is essentially
an extracellular matrix without cellular components. Further
work is required to isolate the LMMC complex and define its
protein and lipid content.
In summary, the MMP Pathway has been shown to be
present in brain tissue with the potential to modulate the free
levels of MMPs that can degrade 𝛽-amyloid. In Alzheimer’s,
preliminary results suggest dysregulation of theMMP system
such that elevated levels of pro-MMP9 are predicted to
compromise activation of MMP2 and thereby reduce the
degradation of 𝛽-amyloid. Further work is now required,
with a much larger donor group, to quantify the levels of
the MMP2 species, and to evaluate the extent to which
dysregulation of the MMP system affects the degradation
potential towards 𝛽-amyloid in Alzheimer’s disease.
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